To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

November 4, 2024

Study Completion Date

November 25, 2024

Conditions
Heart FailureWorsening Heart Failure (WHF)
Interventions
DRUG

Placebo

Matching placebo SC injection

DRUG

R2R01

Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

Trial Locations (18)

19104

Hospital of the University of Pennsylvania, Philadelphia

30309

Piedmont Hospital Transplant, Atlanta

32224

Mayo Clinic, Jacksonville

37232

Vanderbilt University Medical Center, Nashville

48109

University of Michigan Medical Center, Ann Arbor

55905

Mayo Clinic, Rochester

60612

Rush University Medical Center, Chicago

70121

Ochsner Clinic Foundation, New Orleans

75246

VA North Texas Health Care, Dallas

76104

Baylor Scott and White All Saints Medical Center, Fort Worth

85054

Mayo Clinic, Phoenix

94109

California Pacific Medical Center, San Francisco

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Unknown

University of Duisburg-Essen, Essen

University of Munster, Münster

University of Bologna, Bologna

University-Hospital of Padova, Padua

All Listed Sponsors
collaborator

International HealthCare, LLC

OTHER

lead

River 2 Renal Corp.

INDUSTRY

NCT06264310 - To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) | Biotech Hunter | Biotech Hunter